Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 2/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.63 |
| ▸ | MET | P08581 | 10/20 | 0.62 |
| ▸ | AXL | P30530 | 4/20 | 0.62 |
| ▸ | KDR | P35968 | 3/20 | 0.62 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19372993 | 0.91 | FGFR2 (0.62) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL20216881 | 0.91 | FGFR2 (0.60) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL24240698 | 0.90 | FGFR2 (0.62) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL26254832 | 0.90 | FGFR2 (0.62) | FGFR2PDGFRAAXLKDRPDGFRB | |
| SCHEMBL24240657 | 0.89 | FGFR2 (0.59) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL24240624 | 0.89 | FGFR2 (0.58) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL19711775 | 0.89 | MET (0.62) | FGFR2METAXLKDR | |
| SCHEMBL24240665 | 0.88 | FGFR2 (0.57) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL22521210 | 0.88 | FGFR2 (0.57) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL22521303 | 0.88 | FGFR2 (0.57) | FGFR2PDGFRAMETAXLKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220089541-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3914356-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-113710322-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3896059-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2021-10-20 | — | — | EP | disclosed |
| EP-3798218-A1 | FUSED-CYCLIC PYRAZOLONE FORMAMIDE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2021-03-31 | — | — | EP | disclosed |
| WO-2021025407-A1 | OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 웰마커바이오 주식회사 | 2021-02-11 | — | — | WO | disclosed |
| WO-2020154610-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020154610-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. | 2015-07-30 | — | — | US | disclosed |
| US-9029538-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | IGNYTA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| EP-2780338-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | Cephalon, Inc. (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2013074633-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2008035209-A2 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210670-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | FGFR2 201/4885PDGFRA 103/4885MET 5/4885 |
| US-20220089541-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | PRKDC, MAP3K20, BRAF | FGFR2 897/4885PDGFRA 1300/4885MET 367/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | FGFR2 667/4885PDGFRA 779/4885MET 392/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | FGFR2 201/4885PDGFRA 103/4885MET 5/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | FGFR2 36/4885PDGFRA 26/4885MET 3/4885 |
| US-10017496-B2 | Uracil derivatives as AXL and c-MET kinase inhibitors | AXL, RET, FLT3 | FGFR2 158/4885PDGFRA 72/4885MET 5/4885 |
| US-20150209358-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | FGFR2 201/4885PDGFRA 103/4885MET 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.